We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis to End Global Distribution of Generic Zantac Over NDMA Impurity
Novartis to End Global Distribution of Generic Zantac Over NDMA Impurity
Novartis announced Wednesday that it is halting distribution of generic Zantac (ranitidine) globally amid ongoing investigations into ranitidine drugs containing a potential carcinogen.